Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
2014-003233-26Phase 3Completed
- Sponsor
- MedImmune
- Start
- Jan 2015
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of moxetumomab pasudotox in hairy cell leukemia (HCL) and Hairy cell leukemia variant (HCL-V), sponsored by MedImmune. Primary endpoint: Durable complete response. Started Jan 2015; status: completed.
02
Drugs
moxetumomab pasudotox
03
Conditions
hairy cell leukemia (HCL)Hairy cell leukemia variant (HCL-V)
Beyond the preview
Go deeper on 2014-003233-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003233-26.